Display options
Cite
Javkhedkar AA, Banday AA. Antioxidant resveratrol restores renal sodium transport regulation in SHR. Physiol Rep. 2015;3(11)doi: 10.14814/phy2.12618.
Javkhedkar, A. A., & Banday, A. A. (2015). Antioxidant resveratrol restores renal sodium transport regulation in SHR. Physiological reports, 3(11), . https://doi.org/10.14814/phy2.12618
Javkhedkar, Apurva A, and Banday, Anees A. "Antioxidant resveratrol restores renal sodium transport regulation in SHR." Physiological reports vol. 3,11 (2015). doi: https://doi.org/10.14814/phy2.12618
Javkhedkar AA, Banday AA. Antioxidant resveratrol restores renal sodium transport regulation in SHR. Physiol Rep. 2015 Nov;3(11). doi: 10.14814/phy2.12618. Epub 2015 Nov 24. PMID: 26603454; PMCID: PMC4673646.
Copy Download .nbib Format: NLM
Share it on

Physiol Rep. 2015 Nov;3(11). doi: 10.14814/phy2.12618. Epub 2015 Nov 24.

Antioxidant resveratrol restores renal sodium transport regulation in SHR.

Physiological reports

Apurva A Javkhedkar, Anees A Banday

Affiliations

  1. Heart and Kidney Institute, College of Pharmacy, University of Houston, Houston, Texas.
  2. Heart and Kidney Institute, College of Pharmacy, University of Houston, Houston, Texas [email protected].

PMID: 26603454 PMCID: PMC4673646 DOI: 10.14814/phy2.12618

Abstract

Previously we have shown that in spontaneously hypertensive rats (SHR) renal angiotensin (Ang) II receptor (AT1R) upregulation leads to overstimulation of Na/K-ATPase by Ang II. There are reports that antioxidants can reduce oxidative stress and blood pressure (BP) in SHR, however the effect of these compounds on AT1R function remains to be determined. Therefore, we hypothesized that polyphenol antioxidant resveratrol would mitigate oxidative stress, normalize renal AT1R signaling, and reduce BP in SHR. SHR and wistar-kyoto (WKY) rats were treated with resveratrol for 8 weeks. Untreated SHR exhibited oxidative stress and enhanced renal proximal tubular Ang II-induced G-protein activation and Na/K-ATPase stimulation. Treatment of SHR with resveratrol mitigated oxidative stress, reduced BP, and normalized renal AT1R signaling. In SHR, nuclear expression of transcription factor NF-κB was increased while expression of Nrf2 was reduced. SHR also exhibited a significant decrease in renal antioxidant capacity and activities of phase II antioxidant enzymes. Resveratrol treatment of SHR abolished renal NF-κB activation, restored Nrf2-phase II antioxidant signaling and Ang II-mediated Na/K-ATPase regulation. These data show that in SHR, oxidative stress via activation of NF-κB upregulates AT1R-G-protein signaling resulting in overstimulation Na/K-ATPase which contributes to hypertension. Resveratrol, via Nrf2, activates phase II antioxidant enzymes, mitigates oxidative stress, normalizes AT1R-G-protein signaling and Na/K-ATPase regulation, and decreases BP in SHR.

© 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.

Keywords: G proteins; Na/K‐ATPase; hypertension; oxidative stress; transcription factors

References

  1. Curr Atheroscler Rep. 2012 Apr;14(2):160-6 - PubMed
  2. Hypertension. 2003 Jun;41(6):1353-8 - PubMed
  3. Biosci Biotechnol Biochem. 2011;75(8):1435-9 - PubMed
  4. Urol Res. 2012 Apr;40(2):95-112 - PubMed
  5. J Pharmacol Exp Ther. 2012 Jul;342(1):81-90 - PubMed
  6. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
  7. Clin Exp Hypertens. 2006 Jan;28(1):29-40 - PubMed
  8. J Biol Chem. 2005 Mar 18;280(11):9786-95 - PubMed
  9. Am J Physiol Renal Physiol. 2011 Aug;301(2):F364-70 - PubMed
  10. Clin Sci (Lond). 2012 Aug 1;123(4):193-203 - PubMed
  11. Free Radic Biol Med. 2006 Jan 1;40(1):13-20 - PubMed
  12. J Mol Endocrinol. 2009 Aug;43(2):73-80 - PubMed
  13. Anal Biochem. 1978 May;86(1):271-8 - PubMed
  14. Adv Pharmacol. 2012;63:43-79 - PubMed
  15. Can J Cardiol. 2012 May;28(3):288-95 - PubMed
  16. J Am Soc Nephrol. 2012 Oct;23(10):1663-73 - PubMed
  17. Br J Pharmacol. 2012 Nov;167(6):1244-58 - PubMed
  18. Curr Hypertens Rep. 2011 Apr;13(2):122-8 - PubMed
  19. Pflugers Arch. 1977 Jan 17;367(3):295-7 - PubMed
  20. Am J Physiol Renal Physiol. 2012 Jan 1;302(1):F85-94 - PubMed
  21. Compr Physiol. 2014 Jul;4(3):1017-55 - PubMed
  22. Neurochem Res. 2011 Dec;36(12 ):2352-62 - PubMed
  23. Mol Cell Endocrinol. 2012 Mar 24;350(2):151-62 - PubMed
  24. Kidney Int. 2005 Jul;68(1):179-87 - PubMed
  25. Am J Physiol. 1988 Oct;255(4 Pt 2):F666-73 - PubMed
  26. Hypertension. 2008 Dec;52(6):1099-105 - PubMed
  27. J Biol Chem. 2002 Feb 22;277(8):5719-24 - PubMed
  28. Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1219-30 - PubMed
  29. Curr Opin Nephrol Hypertens. 2012 Jan;21(1):7-14 - PubMed
  30. Am J Physiol Renal Physiol. 2012 Jan 1;302(1):F47-51 - PubMed
  31. Hypertension. 2012 Aug;60(2):396-403 - PubMed
  32. Biochem Biophys Res Commun. 1992 Mar 31;183(3):1025-32 - PubMed
  33. Am J Physiol Renal Physiol. 2004 Mar;286(3):F451-7 - PubMed
  34. J Ethnopharmacol. 2011 Oct 11;137(3):1366-72 - PubMed
  35. Immunol Rev. 2012 Mar;246(1):346-58 - PubMed

Publication Types

Grant support